Key points are not available for this paper at this time.
Introduction/Background Gestational trophoblastic tumors (GTTs) represent the malignant forms of gestational trophoblastic diseases. They always follow pregnancy, most often molar (hydatidiform mole). They refer to conditions that have in common an abnormally high and prolonged secretion of chorionic gonadotropic hormone (HCG). They can be divided into two groups: a low-risk group, treated with monochemotherapy, and a high-risk group, treated with multiple chemotherapy. We report the case of 10 patients treated for high-risk TTG Methodology This is a retrospective study of 10 cases, observational and longitudinal spread over a period of 6 years, from January 2018 to December 2023 at the Hassan II University Hospital Center of FES within the obstetric gynecology I department of the Mother-Child Hospital. Results The mean age of onset is 31 1/2 years. The causal pregnancy was in 70% of cases a molar pregnancy. Combination chemotherapy was initiated in 10 patients. All of our patients received clinical and biological monitoring prior to each chemotherapy session; then monthly after negativation every month, up to 18 months One case of death has been reported following a complication of combination chemotherapy such as severe toxiderma. Conclusion This study allowed us to analyze the good follow-up of patients, early diagnosis TTG, especially in the case of follow-up of the moles and especially the prognosis of the patients afterwards Treatment and termination of monitoring Disclosures Department of Obstetrics and Gynecology, Hassan II University Hospital, Fez, Morocco Lead author Dr. Mochtari Houda Resident in Obstetrics and Gynecology I Hassan II University Hospital Center Morocco
Houda Mochtari (Fri,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: